OPC 15161: degradation product of OPC-15160; structure given in first source; superoxide inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 129359 |
| SCHEMBL ID | 9025829 |
| MeSH ID | M0185508 |
| Synonym |
|---|
| opc 15161 |
| 6-(1h-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-4-oxido-1h-pyrazin-4-ium-2-one |
| 6-(1h-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-2-(1h)-pyrazinone 4-oxide |
| 2(1h)-pyrazinone, 6-(1h-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-, 4-oxide |
| 121071-92-9 |
| opc-15161 |
| AFTLYEDBVFGRNK-UHFFFAOYSA-N |
| 6-(indol-3-yl)methyl-3-isobutyl-5-methoxy-1,2-dihydropyrazin-2-one 4-oxide |
| SCHEMBL9025829 |
| DTXSID00153141 |
| PD160674 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||